The oncologist · 2026
Computed tomography-derived body composition and early changes predict outcomes of first-line chemo-immunotherapy in recurrent/metastatic nasopharyngeal carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gan Xia, Yu Zhengzheng, Tang Yaning, Zhang Lin, Xie Wenji, Sun Xiaowen, Li Yue, Fang Jianing, Liu Yating, Liu Zhongjie, Zhou Can, Xie Zhuolong, Yao Wen, Ouyang Shuyu, Zhang Jing, Wang Jingyu, Li Hua, Chen Pan, Wang Hui, Li Yanxian, Liu Huai
Аннотация
BACKGROUND: Reliable biomarkers for risk stratification and treatment monitoring in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) treated with first-line chemo-immunotherapy remain limited. This study evaluated the prognostic value of baseline computed tomography (CT)-derived body composition parameters and their early dynamic changes.
METHODS: In this single-center retrospective cohort study, patients with R/M NPC receiving first-line chemo-immunotherapy were included. The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS), objective response rate (ORR), and disease control rate (DCR). Associations between body composition and outcomes were analyzed.
RESULTS: A total of 199 patients were included, and 99 with post-treatment CT after 2 cycles were further analyzed for dynamic changes. Higher baseline skeletal muscle area (SMA) was independently associated with longer PFS (HR = 0.56; 95% CI, 0.37-0.85; P = 0.006) and OS (HR = 0.46; 95% CI, 0.23-0.93; P = 0.03), and with higher ORR (82.8% vs 70.0%; P = 0.033) and DCR (98.0% vs 91.0%; P = .031). During early treatment, a ≤1.3% decrease or an increase in SMA was independently associated with longer PFS (HR = 0.53; P = 0.045) and OS (HR = 0.27; P = 0.018). A greater decline in visceral adipose tissue density (ΔVATD < -0.9%) was also associated with more favorable PFS and OS, whereas no significant difference in ORR was observed.
CONCLUSION: Baseline SMA and early changes in SMA and VATD have prognostic value in R/M NPC treated with first-line chemo-immunotherapy. CT-based body composition assessment may serve as a practical imaging biomarker for risk re-stratification and individualized management.
METHODS: In this single-center retrospective cohort study, patients with R/M NPC receiving first-line chemo-immunotherapy were included. The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS), objective response rate (ORR), and disease control rate (DCR). Associations between body composition and outcomes were analyzed.
RESULTS: A total of 199 patients were included, and 99 with post-treatment CT after 2 cycles were further analyzed for dynamic changes. Higher baseline skeletal muscle area (SMA) was independently associated with longer PFS (HR = 0.56; 95% CI, 0.37-0.85; P = 0.006) and OS (HR = 0.46; 95% CI, 0.23-0.93; P = 0.03), and with higher ORR (82.8% vs 70.0%; P = 0.033) and DCR (98.0% vs 91.0%; P = .031). During early treatment, a ≤1.3% decrease or an increase in SMA was independently associated with longer PFS (HR = 0.53; P = 0.045) and OS (HR = 0.27; P = 0.018). A greater decline in visceral adipose tissue density (ΔVATD < -0.9%) was also associated with more favorable PFS and OS, whereas no significant difference in ORR was observed.
CONCLUSION: Baseline SMA and early changes in SMA and VATD have prognostic value in R/M NPC treated with first-line chemo-immunotherapy. CT-based body composition assessment may serve as a practical imaging biomarker for risk re-stratification and individualized management.